Company Overview and News


Add TBP
to your dashboard

Headline News

Tetra Bio-Pharma's Business Model and Commercialization Strategy In Line with the Canadian Government's Proposed Approach to the Regulation of Cannabis

2017-11-22 marketwired
OTTAWA, ONTARIO--(Marketwired - Nov. 22, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that the Canadian Government's Proposed Approach to the Regulation of Cannabis further confirms the strategic direction of its business model, and that the company is in an excellent position to commercialize natural health products and drugs post-legalization for both the pet and human markets. (3-0)

Tetra Bio-Pharma Inc.: Rx Princeps(TM) Now Available for Patients through Licenced Producer Partner Aphria

2017-11-16 marketwired
OTTAWA, ONTARIO--(Marketwired - Nov. 16, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that Rx Princeps™, unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc. ("Aphria") under Access to Cannabis for Medical Purposes Regulations (ACMPR). (9-0)

22nd Century Group's (XXII) CEO Henry Sicignano on Q3 2017 Results - Earnings Call Transcript

2017-11-11 seekingalpha
Good day and welcome to the 22nd Century Third Quarter 2017 Business Update. Today’s conference is being recorded. At this time, I would like to turn the conference over to General Counsel of 22nd Century Group, Mr. Tom James. Please go ahead, sir. (462-2)

Tetra Bio-Pharma Concludes its First Sale of Rx Princeps(TM) Inhalation Device

2017-11-09 marketwired
OTTAWA, ONTARIO--(Marketwired - Nov. 9, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced its first sale of its Rx Princeps™ inhalation device. The sale of this inhalation device is the first step towards the sale of Rx Princeps™. (3-0)

Tetra Bio-Pharma Goes After the Cannabis Oil Medical Market and Launches a Phase 4 Trial with Cannabis Oils in Partnership with Santé Cannabis

2017-10-26 marketwired
OTTAWA, ONTARIO--(Marketwired - Oct. 26, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis market. (3-0)

Tetra Bio-Pharma Hires Medical Science Liaison to Promote Rx Princeps(TM) and Presents its New Corporate Image

2017-10-19 marketwired
OTTAWA, ONTARIO--(Marketwired - Oct. 19, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL). (18-0)

Tetra Bio-Pharma Signs Agreement with Partner Aphria to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR

2017-10-18 marketwired
OTTAWA, ONTARIO--(Marketwired - Oct. 18, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR). Tetra has signed a distribution agreement with its trusted partner Aphria to sell Rx Princeps™, its unique blend of dried medical cannabis used in its PPP0001 clinical trials. (9-0)

Tetra Bio-Pharma Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb

2017-10-13 marketwired
OTTAWA, ONTARIO--(Marketwired - Oct. 13, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the addition of two members to its clinical advisory board for the veterinary market - Dr. Cheryl Cullen, an American Board-certified Veterinary Ophthalmologist, and Dr. Webb, an American Board of Veterinary Ophthalmology (ABVO) Resident. (3-0)

Tetra Bio-Pharma Selected to Present at Prestigious BIO Investor Forum In San Francisco October 17-18

2017-10-04 marketwired
OTTAWA, ONTARIO--(Marketwired - Oct. 4, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug discovery, today announced that it has been selected, among a large group of candidates, to present at the prestigious BIO Investor Forum to be held in San Francisco October 17-18th at the Westin St. Francis Hotel. Robert (Bob) Bechard, Vice-President, Finance and Business Development of Tetra will present on Tuesday the 17th at 4:00pm Pacific Time (7:00pm Eastern Time). (3-0)

Tetra Engages in Innovative Air Analysis and Development of Specific Air Cleaning Devices with AES Environment for the Commercialization of PPP001 and for Marijuana Consumer Market

2017-09-28 marketwired
OTTAWA, ONTARIO--(Marketwired - Sept. 28, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with AES Environment Group to develop and commercialize specific products ensuring the safety of caregivers for patients who will use PPP001 or medical cannabis. (18-0)

Tetra Bio-Pharma to engage in co-development and distribution partnership with major healthcare specialty distributor

2017-09-20 marketwired
OTTAWA, ONTARIO--(Marketwired - Sept. 20, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry. (3-0)

Tetra Bio-Pharma getting ready to file a clinical trial application to initiate phase 3 clinical trial on terminal cancer patients in the coming weeks

2017-09-18 marketwired
OTTAWA, ONTARIO--(Marketwired - Sept. 18, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announces that it will be filing a clinical trial application (CTA) in the coming weeks to therapeutic products directorate (TPD) to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients. With this filing, Tetra expects to be on time with its previously announced schedule with the development of PPP001. (3-0)

Tetra Bio-Pharma Announces Approval to List on the TSX Venture Exchange

2017-08-16 marketwired
OTTAWA, ONTARIO--(Marketwired - Aug. 16, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that its common shares have been approved for trading on the TSX Venture Exchange and that it has applied for voluntary delisting of its common shares from the Canadian Securities Exchange (CSE). Tetra's shares will commence trading on the TSX Venture on the opening of markets on Wednesday, August 16, 2017, under the symbol "TBP".

University of New Brunswick announces cannabis research chair

2017-08-09 globalnews.ca
The University of New Brunswick has announced the university will have a Cannabis Health Research Chair.

Tetra Bio-Pharma CSO Discusses Opportunities in Exclusive CFN Media Interview

2017-07-26 marketwired
SEATTLE, WA--(Marketwired - Jul 26, 2017) -  CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article and exclusive interview covering Tetra Bio-Pharma Inc. (CSE: TBP) (CSE: TBP.CN) (CNSX: TBP) (OTCQB: TBPMF). The interview, with Chief Science Officer Dr. Guy Chamberland, and article discuss the company's progress in advancing its clinical pipeline designed to bring innovative cannabis products to market.